Parallax Volatility Advisers
FPRX

Parallax Volatility Advisers’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Parallax Volatility Advisers’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-45,000
Closed -$626K – 4309
2018
Q3 		$626K Hold
45,000
– – ﹤0.01% 1385
2018
Q2 		$711K Buy
+45,000
New +$785K ﹤0.01% 1183

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Parallax Volatility Advisers's FPRX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 4,524 shares — an estimated $99K sold.

Parallax Volatility Advisers first reported a position in FPRX in Q4 2017 and held it in 1 quarter. The position peaked at $99K in Q4 2017. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 4,524 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $99K.
  • Parallax Volatility Advisers first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Five Prime Therapeutics, Inc. position peaked at $99K in Q4 2017.
  • 128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.